Improve Cancer-related Cognitive Impairment
NCT05864274
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Cancer-related cognitive impairment (CRCI), also known as "chemobrain," is the cognitive decline that negatively impacts the majority of cancer patients undergoing chemotherapy, radiation, and/or hormonal treatments. This application focuses on evaluating if using a cognitive mobile training application can decrease the impact of CRCI in gynecologic oncology patients through a multidisciplinary approach with patients undergoing assessments by our neurocognitive team.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Gynecologic Cancer
- Chemotherapy Effect
- Chemo-brain
- Cancer-related Cognitive Difficulties
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 to 90 years
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- University of Alabama at Birmingham
- Last updated on ClinicalTrials.gov
- November 24, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama at Birmingham · Birmingham, AL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.